1-(苄氧基)-4-溴-2-甲氧基苯 | 63057-72-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 1-(苄氧基)-4-溴-2-甲氧基苯
• 英文名称: 2-benzyloxy-5-bromoanisole
• 英文别名: 1-(benzyloxy)-4-bromo-2-methoxybenzene；4-benzyloxy-3-methoxybromobenzene；4-bromo-2-methoxy-1-phenylmethoxybenzene
• CAS: 63057-72-7
• 化学式: C₁₄H₁₃BrO₂
• 分子量: 293.16
• InChiKey: AEGJXXCGTFMRGY-UHFFFAOYSA-N

物化性质

• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2909309090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  存于室温下，应保持干燥并密封保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-(Benzyloxy)-4-bromo-2-methoxybenzene
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-(Benzyloxy)-4-bromo-2-methoxybenzene
CAS number: 63057-72-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C14H13BrO2
Molecular weight: 293.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(苄氧基)-4-溴-2-甲氧基苯 在 碘 、 magnesium 作用下， 以 四氢呋喃 为溶剂， 生成 [4-(benzyloxy)-3-methoxyphenyl]magnesium bromide
  参考文献：
  名称：

  9H-PYRIMIDO[4,5-B]INDOLES AND RELATED ANALOGS AS BET BROMODOMAIN INHIBITORS

  摘要：

  本公开提供了代表为式I的替代的9H-嘧啶并[4,5-b]吲哚和5H-吡啶并[4,3-b]吲哚及相关类似物的药用可接受的盐、水合物和溶剂合物，其中R1a、A、B1、B2、G、X1、Y1、Y2和Y3如规范中所定义。本公开还涉及使用式I的化合物来治疗对BET溴结构域抑制敏感的状况或疾病。本公开的化合物特别适用于治疗癌症。

  公开号：

  US20150246923A1
• 作为产物：
  描述：

  木榴油 在 溴 、 potassium carbonate 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.0h， 生成 1-(苄氧基)-4-溴-2-甲氧基苯
  参考文献：
  名称：

  Structure-Based Design, Docking and Binding Free Energy Calculations of A366 Derivatives as Spindlin1 Inhibitors

  摘要：

  染色质阅读蛋白Spindlin1在表观遗传调控中扮演重要角色，已与多种恶性肿瘤相关。在当前工作中，我们报道了先前发表的主要抑制剂A366的新类似物的开发。为了提高活性并探索结构-活性关系（SAR），合成了一系列21个衍生物，在体内进行了测试，并通过分子建模工具进行了研究。进行了对接研究和分子动力学（MD）模拟，以分析和理解负责Spindlin1活性的结构差异。MD模拟的分析揭示了重要的相互作用。我们的研究突出显示了用于Spindlin1抑制活性所需的主要结构特征，其中包括嵌入芳香笼中的带正电的吡咯烷基，通过丙氧基连接到2-氨基吲哚核心。在后者中，酰胺基固定化合物到通过与Asp184的盐桥相互作用的口袋中。测试了不同的协议以识别一种快速的计算机辅助方法，可以帮助区分A366系列中的活性和非活性化合物。使用MM-GBSA计算重新评分对接姿势在这方面取得了成功。由于A366被认为是G9a的抑制剂，因此还测试了最活跃的开发的Spindlin1抑制剂对G9a和GLP的选择性配置文件进行验证A366类似物。这导致了多种选择性化合物的发现，其中1s和1t显示出纳摩尔级别的Spindlin1活性，并且对G9a和GLP具有选择性。最后，基于我们的发现提出了未来的设计假设。

  DOI：

  10.3390/ijms22115910

文献信息

• Rapid Access to Benzofuran-Based Natural Products through a Concise Synthetic Strategy
  作者：Maddali L. N. Rao、Venneti N. Murty

  DOI：10.1002/ejoc.201600154

  日期：2016.4

  A concise strategy is described for the synthesis of ailanthoidol (1), egonol (2), homoegonol (3), demethoxyegonol (4), demethoxyhomoegonol (5), and stemofuran A (6). This approach involves a Pd-catalysed domino cyclization/coupling process using triarylbismuth reagents for the generation of the benzofuran core. Subsequent structural modifications then give the final targets. The high yielding synthesis

  描述了用于合成臭椿素 (1)、egonol (2)、homoegonol (3)、demethoxyegonol (4)、demethoxyhomoegonol (5) 和 Stemofuran A (6) 的简明策略。该方法涉及使用三芳基铋试剂生成苯并呋喃核的 Pd 催化的多米诺环化/偶联过程。随后的结构修改然后给出最终目标。最近分离的天然产物 egonol-9(Z)-12(Z)-linoleate (2a)、7-demethoxyegonol-9(Z)-12(Z)-linoleate (4a) 和 7-demethoxyegonol-9(Z)-12(Z)-linoleate (4a) 的高产合成-egonol-9(Z)-油酸酯 (4b) 也有报道。
• Synthesis of Lignans Based on a Borate‐mediated One‐pot Sequential Suzuki‐Miyaura Coupling of Cyclic Boranes
  作者：Ko Sato、Hiroshi Tanaka

  DOI：10.1002/chem.202100804

  日期：2021.6.25

  phytochemicals that possess a large spectrum of chemical structures and biological activities. Here the syntheses of lignans – anwulignan, burseran, dehydroxycubebin, ruburisandrin B, and sesamin – are achieved based on a borate-mediated one-pot sequential Suzuki-Miyaura coupling of cis- and trans-fused bicyclic boranes, which were prepared by diastereoselective cyclic hydroboration of exo-cyclic diene with

  木脂素是一组多酚类植物化学物质，具有广泛的化学结构和生物活性。在这里，木脂素的合成——anwulignan、burseran、dehydroxycubebin、ruburisandrin B 和芝麻素——是基于硼酸盐介导的顺式和反式一锅序贯 Suzuki-Miyaura 偶联实现的-稠合双环硼烷，分别通过环戊基-和甲苯基硼烷对环外二烯进行非对映选择性环状硼氢化反应制备。每个环状硼酸酯与各种芳基溴化物的一锅顺序 Suzuki-Miyaura 偶联通过用碳亲核试剂活化环状硼烷引发，提供具有不同芳族取代基的 2,3-二苄基丁烷衍生物。最后，从 Suzuki-Miyaura 偶联的产物中分几个步骤完成了天然存在的木脂素的合成。
• [EN] COMPOUNDS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION<br/>[FR] COMPOSÉS POUR TRAITER UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B
  申请人：GILEAD SCIENCES INC

  公开号：WO2018144605A1

  公开（公告）日：2018-08-09

  The present disclosure generally relates to compounds and pharmaceutical compositions which may be used in methods of treating a hepatitis B virus infection.

  本公开涉及一般与化合物和药物组合物有关，这些化合物和药物组合物可用于治疗乙型肝炎病毒感染的方法。
• Piperazine derivatives
  申请人：Middleton Stuart Donald

  公开号：US20050043300A1

  公开（公告）日：2005-02-24

  This invention relates to a compound of formula (I) or pharmaceutically acceptable salts, solvates or derivatives thereof, wherein R 1 to R 5 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation, compositions containing them and the uses of such derivatives. The compounds of the present invention inhibit the interaction of gp120 with CD4 and are therefore of use in the treatment of HIV, a retroviral infection genetically related to HIV, or AIDS.

  这项发明涉及一种具有化学式(I)的化合物 或其药用可接受的盐、溶剂合物或衍生物，其中R 1 至R 5 在描述中有定义，并涉及其制备方法、制备中使用的中间体、含有它们的组合物以及这些衍生物的用途。 本发明的化合物抑制gp120与CD4的相互作用，因此在治疗HIV、与HIV有遗传关系的逆转录病毒感染或艾滋病方面有用。
• Catechol derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US05236952A1

  公开（公告）日：1993-08-17

  Catechol derivatives of the formula ##STR1## wherein Ra, Rb and Rc have the significance given herein, the ester and ether derivatives thereof which are hydrolyzable under physiological conditions and the pharmaceutically acceptable salts thereof are described and possess valuable pharmacological properties. In particular, they inhibit the enzyme catechol-O-methyltransferase (COMT), a soluble, magnesium-dependent enzyme which catalyses the transference of the methyl group of S-adensoylmethionine to a catechol substrate, whereby the corresponding methyl ethers are formed. Suitable substrates which can be O-methylated by COMT and which can thus be deactivated are, for example, extraneuornal catecholamines and exogeneously-administered therapeutically active substances having a catechol structure. Formula Ia above embraces not only compounds which form part of the invention, but also known compounds; the compounds which form part of the invention can be prepared according to known methods.

  公式##STR1##中的儿茶酚衍生物，其中Ra、Rb和Rc具有本文中给出的含义，以及在生理条件下可水解的酯和醚衍生物及其药学上可接受的盐已被描述，并具有有价值的药理特性。特别是，它们抑制儿茶酚-O-甲基转移酶(COMT)这种可溶性、依赖镁的酶，该酶催化S-腺苷甲硫氨酸的甲基基团转移到儿茶酚底物上，从而形成相应的甲基醚。可被COMT进行O-甲基化并因此被失活的适当底物包括，例如，外源性儿茶酚胺和具有儿茶酚结构的外源性给药的治疗活性物质。上述公式Ia不仅包括发明的一部分化合物，还包括已知的化合物；构成发明一部分的化合物可以按照已知方法制备。